Simon N Robinson
Overview
Explore the profile of Simon N Robinson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
550
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Macro optical projection tomography for large scale 3D imaging of plant structures and gene activity
Lee K, Calder G, Hindle C, Newman J, Robinson S, Avondo J, et al.
J Exp Bot
. 2016 Dec;
68(3):527-538.
PMID: 28025317
Optical projection tomography (OPT) is a well-established method for visualising gene activity in plants and animals. However, a limitation of conventional OPT is that the specimen upper size limit precludes...
2.
Robinson S, Thomas M, Simmons P, Lu J, Yang H, Javni J, et al.
Cytotherapy
. 2016 Dec;
19(2):285-292.
PMID: 27919572
Background Aims: Despite ethnic diversity and ready availability of cryopreserved, human leukocyte antigen-typed cord blood (CB), delayed engraftment remains a significant hurdle to successful CB transplantation. Suboptimal homing of CB...
3.
Simmons P, Robinson S, Munsell M, Thomas M, Javni J, Brouard N, et al.
Stem Cells Dev
. 2015 Feb;
24(9):1066-72.
PMID: 25674667
CD34(+) cell dose provides a measure of hematopoietic tissue that predicts the rate of engraftment upon transplant. It is positively correlated with multiple measures of hematopoietic recovery, including platelet engraftment....
4.
Parmar S, Liu X, Tung S, Robinson S, Rodriguez G, Cooper L, et al.
Cytotherapy
. 2014 Feb;
16(1):90-100.
PMID: 24480547
Background Aims: Naturally occurring regulatory T cells (Treg) are emerging as a promising approach for prevention of graft-versus-host disease (GvHD), which remains an obstacle to the successful outcome of allogeneic...
5.
Shah N, Martin-Antonio B, Yang H, Ku S, Lee D, Cooper L, et al.
PLoS One
. 2013 Nov;
8(10):e76781.
PMID: 24204673
Natural killer (NK) cells are important mediators of anti-tumor immunity and are active against several hematologic malignancies, including multiple myeloma (MM). Umbilical cord blood (CB) is a promising source of...
6.
Robinson S, Thomas M, Simmons P, Lu J, Yang H, Parmar S, et al.
Cytotherapy
. 2013 Oct;
16(1):84-9.
PMID: 24094497
Background Aims: Advantages associated with the use of cord blood (CB) transplantation include the availability of cryopreserved units, ethnic diversity and lower incidence of graft-versus-host disease compared with bone marrow...
7.
Decker W, Shah N, Xing D, Lapushin R, Li S, Robinson S, et al.
PLoS One
. 2013 Jan;
7(12):e51390.
PMID: 23284688
Though remissions have been observed following allo-HSCT for the treatment of CLL, many CLL patients are ineligible for transplant due to the lack of HLA-compatible donors. The use of umbilical...
8.
de Lima M, McNiece I, Robinson S, Munsell M, Eapen M, Horowitz M, et al.
N Engl J Med
. 2012 Dec;
367(24):2305-15.
PMID: 23234514
Background: Poor engraftment due to low cell doses restricts the usefulness of umbilical-cord-blood transplantation. We hypothesized that engraftment would be improved by transplanting cord blood that was expanded ex vivo...
9.
Robinson S, Simmons P, Thomas M, Brouard N, Javni J, Trilok S, et al.
Exp Hematol
. 2012 Feb;
40(6):445-56.
PMID: 22306295
Delayed engraftment remains a major hurdle after cord blood (CB) transplantation. It may be due, at least in part, to low fucosylation of cell surface molecules important for homing to...
10.
Yang H, Robinson S, Nieto Y, Jones R, Gocke C, Lu J, et al.
Cancer Res
. 2011 Jun;
71(14):5040-9.
PMID: 21646477
Autologous peripheral blood progenitor cell (PBPC) transplantation is the treatment of choice for selected myeloma patients. However, tumor cells contaminating the apheresis product are a potential source of relapse. Here...